a Department of Pharmacy , Sumandeep Vidyapeeth , Vadodara , India.
Drug Dev Ind Pharm. 2018 Apr;44(4):687-696. doi: 10.1080/03639045.2017.1408643. Epub 2017 Dec 4.
The objective of this work was to utilize a potential of microemulsion for the improvement in oral bioavailability of raloxifene hydrochloride, a BCS class-II drug with 2% bioavailability. Drug-loaded microemulsion was prepared by water titration method using Capmul MCM C8, Tween 20, and Polyethylene glycol 400 as oil, surfactant, and co-surfactant respectively. The pseudo-ternary phase diagram was constructed between oil and surfactants mixture to obtain appropriate components and their concentration ranges that result in large existence area of microemulsion. D-optimal mixture design was utilized as a statistical tool for optimization of microemulsion considering oil, S, and water as independent variables with percentage transmittance and globule size as dependent variables. The optimized formulation showed 100 ± 0.1% transmittance and 17.85 ± 2.78 nm globule size which was identically equal with the predicted values of dependent variables given by the design expert software. The optimized microemulsion showed pronounced enhancement in release rate compared to plain drug suspension following diffusion controlled release mechanism by the Higuchi model. The formulation showed zeta potential of value -5.88 ± 1.14 mV that imparts good stability to drug loaded microemulsion dispersion. Surface morphology study with transmission electron microscope showed discrete spherical nano sized globules with smooth surface. In-vivo pharmacokinetic study of optimized microemulsion formulation in Wistar rats showed 4.29-fold enhancements in bioavailability. Stability study showed adequate results for various parameters checked up to six months. These results reveal the potential of microemulsion for significant improvement in oral bioavailability of poorly soluble raloxifene hydrochloride.
本工作旨在利用微乳液的潜力来提高盐酸雷洛昔芬(一种生物利用度为 2%的 BCS 类 II 药物)的口服生物利用度。通过水滴定法用 Capmul MCM C8、Tween 20 和聚乙二醇 400 分别作为油相、表面活性剂和助表面活性剂制备载药微乳液。在油相与表面活性剂混合物之间构建伪三元相图,以获得适当的组成及其浓度范围,从而使微乳液的存在区域较大。D-最优混合设计被用作一种统计工具,用于优化微乳液,考虑油、S 和水作为独立变量,以透光率和液滴尺寸作为依赖变量。优化的配方显示 100±0.1%的透光率和 17.85±2.78nm 的液滴尺寸,与设计专家软件给出的依赖变量的预测值完全相同。与普通药物混悬剂相比,优化的微乳液显示出明显的释放速率增强,遵循 Higuchi 模型的扩散控制释放机制。配方显示出值为-5.88±1.14mV 的 ζ 电位,这赋予载药微乳液分散体良好的稳定性。透射电子显微镜的表面形态研究显示出离散的球形纳米尺寸液滴,表面光滑。在 Wistar 大鼠中的优化微乳液制剂的体内药代动力学研究表明,生物利用度提高了 4.29 倍。稳定性研究表明,在长达六个月的时间内,各种参数的检查结果都足够。这些结果表明微乳液具有显著提高难溶性盐酸雷洛昔芬口服生物利用度的潜力。